Perimenopause vs menopause is not a comparison between two phases. It is a comparison between a multi-year transition and a single moment in time, identified only in hindsight. Perimenopause is the menopausal transition: a span of fluctuating hormones and irregular cycles that typically lasts four to eight years. Menopause, by contrast, is one day. It is the date marking twelve consecutive months without a menstrual period. Everything after that day is post-menopause. The distinction matters because it shapes how you are diagnosed, when pregnancy is still possible for you, and whether the evidence base on hormone therapy applies to you.
Free interactive tool
Which stage am I in?
Answer a few questions about your periods to see which STRAW+10 stage your answers match.
At a glance
- Perimenopause is the menopausal transition and typically lasts four to eight years before the final menstrual period. Menopause is the single date of that final period, confirmed only after twelve months without bleeding (STRAW+10, Harlow et al., 2012).
- The average age of the final menstrual period in the United States is 51 to 52, with a normal range from 45 to 55, according to the Menopause Society (NAMS).
- No single blood test can stage perimenopause. STRAW+10 treats menstrual pattern as the primary criterion and hormone testing as a supportive marker (Harlow et al., 2012).
- Pregnancy stays possible throughout perimenopause. CDC contraception guidance reviewed in 2024 states that contraception is still needed past age 44, and that no reliable laboratory tests confirm definitive loss of fertility.
- The timing hypothesis, endorsed in the Menopause Society's 2022 position statement, holds that the benefit-risk profile of menopausal hormone therapy is most favorable when therapy starts under age 60 or within ten years of the final menstrual period (Manson et al., JAMA, 2017).
In this article
- The simple definition that gets the language right
- Perimenopause, menopause and post-menopause side by side
- The STRAW+10 staging framework: all seven stages
- How FSH, estradiol, progesterone, and AMH behave across each stage
- Why menopause is diagnosed retrospectively, not in real time
- The "timing hypothesis" and what the WHI re-analysis showed
- What changed on the hormone therapy label in 2025 and 2026
- Pregnancy risk during and after the transition
- When the peri-versus-post distinction changes clinical decisions
The simple definition: peri is the transition, menopause is one moment in time
The clearest way to separate the two terms is this. Perimenopause describes the years of reproductive aging during which your ovaries lose follicular reserve and your cycles become irregular. Menopause is the date of your final menstrual period (FMP), confirmed only after twelve months of amenorrhea have passed. The interval after that date is post-menopause. The phrase "going through menopause", while culturally universal, almost always refers to perimenopause, not menopause itself.
According to the Menopause Society (NAMS), the average age of the final menstrual period in the United States is 51 to 52, with a normal range from 45 to 55. Perimenopause may begin in your late 30s and typically lasts four to eight years before the FMP. Premature menopause refers to an FMP before age 40. Early menopause refers to an FMP between 40 and 45.
This terminology is not pedantic. Insurance coding, clinical trial eligibility, contraceptive guidance, and hormone therapy risk-benefit calculations all hinge on which side of the FMP you sit.
The table below sets the three stages against each other on the points that change a decision.
| Comparison point | Perimenopause | Menopause | Post-menopause |
|---|---|---|---|
| What it is | The transition: years of fluctuating hormones and increasingly irregular cycles. | One day: the date of your final menstrual period. | Everything after that date. |
| Typical age | Can start in your late 30s, most often your 40s. | Average 51 to 52, with a normal range of 45 to 55. | From the final period onward. |
| How long it lasts | Typically four to eight years. | A single date, not a span. | The rest of your life. |
| How it is diagnosed | By menstrual pattern over time. STRAW+10 states that no single blood test can stage it. | Retrospectively, twelve months after the final period. | Confirmed once those twelve months have passed. |
| Hormone picture | Estradiol swings, FSH variable and rising, progesterone falls first, AMH low. | The crossover: FSH still rising, estradiol still falling. | FSH stably high, estradiol low, AMH undetectable. |
| Can you get pregnant | Yes. Ovulation is irregular but it has not stopped. | Recognized only in hindsight, so the twelve-month rule decides. | No. Not considered a clinical possibility. |
| Contraception advice | Continue it if you are avoiding pregnancy. CDC 2024 guidance: still needed past age 44. | Stop after twelve months without a period if you are over 50, or twenty-four months if you are under 50. | Not needed for pregnancy. Barrier methods still guard against infection. |
| Where the hormone therapy timing evidence applies | Inside the window: under 60, and within ten years of the final period. | This date starts the ten-year clock the evidence uses. | Most favorable early. The 2024 WHI review does not back starting later to prevent disease. |
The STRAW+10 staging framework: all seven stages explained
The Stages of Reproductive Aging Workshop +10 (STRAW+10) framework, published in 2012, is the international standard for staging female reproductive aging. It identifies seven stages, with the final menstrual period as Stage 0. It is endorsed by NAMS, the International Menopause Society, the Endocrine Society, and the American Society for Reproductive Medicine.
| Stage | Name | Typical age range | Defining features |
|---|---|---|---|
| −3 | Late reproductive | Late 30s to mid-40s | Subtle changes in cycle length or flow; declining AMH and antral follicle count; FSH variable but rising on early follicular days |
| −2 | Early menopausal transition (early peri) | Mid- to late 40s | Persistent cycle-length variability of ≥7 days between consecutive cycles; FSH variable and elevated |
| −1 | Late menopausal transition (late peri) | Late 40s to early 50s | One or more intervals of amenorrhea ≥60 days; vasomotor symptoms most likely; FSH often >25 IU/L |
| 0 | Final menstrual period (FMP) | Average 51–52 | The last menstrual bleed, identified only retrospectively after 12 months of amenorrhea |
| +1a | Early post-menopause (first year) | FMP + 0–1 year | Completion of the 12-month amenorrhea interval; FSH continues to rise; estradiol continues to fall |
| +1b | Early post-menopause (years 2–6) | FMP + 1–6 years | Vasomotor symptoms remain common; FSH and estradiol stabilize at post-menopausal values |
| +1c / +2 | Late post-menopause | FMP + 6+ years | Genitourinary syndrome of menopause becomes more prevalent; somatic aging predominates over reproductive aging |
STRAW+10 explicitly notes that single-day blood tests cannot stage perimenopause accurately. Menstrual pattern is the primary criterion, with hormone testing as a supportive marker (Harlow et al., 2012).
The STRAW+10 stages plotted against typical age
Typical age ranges from the table above, anchored to a final menstrual period at 51 to 52 (the normal range is 45 to 55). Stages overlap because the framework is defined by cycle pattern, not by age; your own timing can sit well outside these bands.
Interactive tool
Which stage am I in?
Answer a few questions about your periods to see which STRAW+10 stage your answers match.
Hormone behavior at each stage
Most online summaries describe perimenopause as "declining estrogen." The reality is more chaotic. Estradiol fluctuates widely, sometimes higher than your reproductive baseline, before falling. FSH rises but is highly variable cycle to cycle. Progesterone declines earliest, because anovulatory cycles become more frequent. Anti-Müllerian hormone (AMH), a marker of your remaining follicle pool, falls steadily from the late reproductive stage onward. The Study of Women's Health Across the Nation (SWAN) longitudinal cohort is the largest dataset describing these trajectories.
| Hormone | Late reproductive (Stage −3) | Perimenopause (Stages −2/−1) | Early post-menopause (+1a/+1b) | Late post-menopause (+1c/+2) |
|---|---|---|---|---|
| FSH | Normal early-follicular range; subtle rise on cycle day 3 | Variable and rising; spikes followed by drops | Persistently elevated, typically >25 IU/L | Stably elevated |
| Estradiol (E2) | Mostly normal; occasional high readings | Highly fluctuating; can be higher OR lower than reproductive baseline | Low and stabilizing | Persistently low |
| Progesterone | Begins to decline as anovulatory cycles appear | Frequently low due to anovulation | Negligible from ovarian source | Negligible |
| AMH | Declining | Low | Often undetectable | Undetectable |
The Endocrine Society clinical practice guidelines caution against diagnosing perimenopause from a single hormone panel. Menstrual history, age, and symptom pattern are the primary criteria; labs corroborate.
How menopause is actually diagnosed: the 12-month rule
Menopause is a retrospective diagnosis. The Menopause Society and STRAW+10 define it as the point twelve consecutive months after the final menstrual period, in the absence of another cause. No blood test, ultrasound, or symptom checklist can declare you menopausal in real time while you are still menstruating.
Several practical implications follow:
- If you have not bled in eleven months, you are still in late perimenopause (Stage −1), not menopause.
- Hormonal contraception, hysterectomy with ovarian preservation, endometrial ablation, and the levonorgestrel IUD all obscure menstrual cues. In these cases clinicians rely on symptom pattern plus selective FSH testing, recognizing the limits of any single value.
- Bleeding twelve or more months after the apparent FMP is post-menopausal bleeding, and it always needs evaluation. An ACOG clinical practice update of April 2026 changed how that evaluation starts. Transvaginal ultrasound and endometrial sampling are now recommended together as the initial step in most patients. Ultrasound alone is reserved for a single episode with a fully visualized endometrium of 4 mm or less and no strong risk factors. On its own, ultrasound misses 5 to 12% of cancers.
Why the "timing hypothesis" matters for hormone therapy decisions
The timing hypothesis is the finding that the risk-benefit profile of menopausal hormone therapy depends on how old you are, and on how long it has been since menopause, when you start it. The Menopause Society endorsed the timing hypothesis in its 2022 position statement, where it is also called the window of opportunity. That is why perimenopause, early post-menopause and late post-menopause each carry a different hormone therapy calculation.
The most consequential reason to distinguish peri, early post-menopause, and late post-menopause is that the evidence on menopausal hormone therapy (MHT) depends on age and timing. The original Women's Health Initiative (WHI) trials, published in the early 2000s, reported increased cardiovascular and breast cancer risks with combined hormone therapy. Later stratified analyses showed those risk estimates were driven largely by women in their 60s and 70s who started therapy a decade or more after menopause.
In 2017, Manson and colleagues published an 18-year follow-up of the WHI cohorts in JAMA. The pooled analysis found no significant increase in all-cause, cardiovascular, or cancer mortality among women randomized to hormone therapy. It also found signals of reduced all-cause mortality in women who started therapy before age 60 or within ten years of menopause onset. The Menopause Society's 2022 position statement now formally endorses this "timing hypothesis", or "window of opportunity". The benefit-risk profile of MHT is most favorable when it is started in symptomatic women under 60 or within ten years of the FMP, in the absence of contraindications.
In 2024, Manson and colleagues published a 30-year review of the Women's Health Initiative in JAMA. It draws on 161,808 enrolled women and up to 20 years of follow-up. It speaks to about 55 million postmenopausal women in the United States. The review supports starting hormone therapy before age 60 for bothersome symptoms, in the absence of contraindications. It does not support hormone therapy for preventing cardiovascular disease or other chronic disease. Both halves of that conclusion matter (NHLBI summary of the 2024 review).
What changed on the hormone therapy label in 2025 and 2026
On 10 November 2025 the FDA removed the boxed warnings for cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products. The first six relabeled products were approved on 12 February 2026. The new labeling cites reduced all-cause mortality and fewer fractures when therapy starts within ten years of menopause or before age 60. The endometrial cancer warning is retained for systemic estrogen-alone products.
The FDA framed the change around a treatment gap. In 2020 about 41 million women in the United States were aged 45 to 64, yet only about 2 million received a hormone therapy prescription. A label change is not a recommendation for you. It changes the warning, not your own risk profile.
The professional guidance has not been rewritten to match. As of September 2026, The Menopause Society's hormone therapy position statement is still the 2022 edition, the one that endorses the timing hypothesis above. Its November 2025 statement supports removing the warning on low-dose vaginal estrogen. The label has moved ahead of the position statement, and your clinician is reading both.
This is evidence to discuss, not a prescription. Your personal and family history of breast cancer, thromboembolic disease, cardiovascular disease, and migraine with aura, and your own symptom burden, all weigh into the calculation. If you are considering hormone therapy, it is worth discussing the timing-hypothesis evidence with your prescribing physician, who can interpret the data against your personal risk profile.
Hormone therapy is also no longer the only prescription route for hot flashes. The FDA approved elinzanetant, a nonhormonal drug sold as Lynkuet, on 24 October 2025. In trials it reduced hot flashes by 3.2 more per 24 hours than placebo at week 12. Reported side effects were headache, fatigue, dizziness and drowsiness (FDA drug trials snapshot). Whether it suits you is a question for your prescribing clinician.
Can you still get pregnant during perimenopause? And after?
Yes. Perimenopause is not a contraceptive state. Ovulation becomes irregular but does not stop until the final menstrual period, and you cannot know in real time that any given cycle is your last. CDC and NAMS guidance state that pregnancy remains possible throughout perimenopause. Contraception should continue until either twelve consecutive months of amenorrhea if you are over 50, or twenty-four consecutive months if you are under 50. Sporadic ovulation is more likely in the younger group.
The CDC contraception guidance reviewed in 2024 is direct about the uncertainty here. If you are avoiding pregnancy, contraception is still needed past age 44. The median age at definitive loss of natural fertility is 41, but it runs as late as 51. The CDC also states that no reliable laboratory tests are available to confirm definitive loss of fertility.
After the 12-month threshold, spontaneous pregnancy is no longer considered a clinical possibility. Any bleeding from that point forward is evaluated as post-menopausal bleeding. Sexually transmitted infection risk does not decline with reproductive aging, so barrier methods remain appropriate regardless of pregnancy potential.
When the distinction matters for clinical decisions
Several clinical pivots hinge on whether a patient is in late perimenopause, early post-menopause, or late post-menopause:
- Contraceptive counseling. Continue contraception in perimenopause; reassess at the 12-month amenorrhea threshold.
- Evaluation of abnormal bleeding. SWAN reported in 2025 that about one in three women has abnormal uterine bleeding during the transition. In that cohort of 1,200 women, prolonged bleeding carried a hazard ratio of 2.35 for later hysterectomy. Heavy or irregular bleeding in late perimenopause warrants endometrial assessment. Any bleeding after the 12-month threshold is post-menopausal bleeding until proven otherwise, evaluated by the ACOG April 2026 route above.
- Hormone therapy candidacy. The timing hypothesis applies; risk-benefit shifts with years since FMP.
- Bone health screening. The USPSTF osteoporosis screening recommendation of January 2025 sets two paths. If you are 65 or older, DXA screening is recommended, a Grade B recommendation. If you are postmenopausal and under 65, it is recommended only when a clinical risk assessment shows increased risk, also Grade B. Osteoporosis affects 27.1% of women aged 65 and over, and only 40 to 60% of people regain mobility after a hip fracture.
- Cardiovascular risk stratification. A May 2026 analysis in the Journal of the American Heart Association found that heart health scores are already falling during perimenopause, not only after it. Median Life's Essential 8 scores were 73.3 before the transition, 69.1 during perimenopause and 63.9 after it. Perimenopausal women had roughly twice the odds of a poor overall score, an adjusted odds ratio of 1.92. That subgroup was small, at 205 women. An August 2026 editorial argues that age rather than the transition drives the rise in cardiovascular risk, so it stays an open question. Lipid and blood pressure surveillance through the transition is reasonable either way.
- Genitourinary syndrome of menopause. More prevalent in late post-menopause; clinical approach differs from vasomotor symptoms of early transition.
What functional medicine practitioners look for
A functional medicine evaluation at any STRAW+10 stage typically extends beyond the conventional menopause workup. Common areas of assessment include:
- Cycle pattern history over the prior 24 months, mapped to STRAW+10 stage
- Symptom inventory: vasomotor, sleep, mood, cognitive, genitourinary, musculoskeletal
- Hormone panel interpreted in the context of cycle timing and STRAW+10 stage, recognizing single-value limitations
- Thyroid function, which often mimics or amplifies perimenopausal symptoms
- Metabolic markers (fasting insulin, HbA1c, lipids) given the increased cardiometabolic risk at and after the transition
- Inflammatory and micronutrient markers as supported by published literature
- Bone health baseline and risk factors
- Family history of breast cancer, cardiovascular disease, thromboembolism, and osteoporosis to inform any future hormone therapy discussion
This is framework-level information. Specific testing, interpretation, and any treatment decisions belong to the clinical encounter and to the prescribing clinician.
When to consider booking a consult
A deeper workup may be warranted if several of the following apply to you:
- Cycles have become noticeably irregular or heavier, and standard evaluation has not clarified the cause
- Vasomotor symptoms, sleep disruption, or mood change are interfering with daily function
- There is uncertainty about STRAW+10 stage or whether menopause has been reached
- You are considering a hormone therapy decision and want to understand the timing-hypothesis evidence before discussing it with a prescribing clinician
- Cycles stopped before age 45, suggesting early menopause
- Symptoms persist years into post-menopause and have not been addressed
- Bone, cardiometabolic, or cognitive concerns have emerged around the transition
Frequently asked questions
Is perimenopause the same as menopause?
No. Perimenopause is the multi-year menopausal transition, characterized by fluctuating hormones and increasingly irregular cycles. Menopause is the single day of your final menstrual period, identified retrospectively after twelve consecutive months without a period. Everything after that day is post-menopause. The cultural use of the word "menopause" to mean "the change" is imprecise. Most symptomatic women are technically in perimenopause, not menopause itself. The distinction matters for diagnosis, contraception decisions, and how the evidence on hormone therapy applies to you (NAMS, 2022).
How is menopause diagnosed?
Menopause is diagnosed retrospectively, twelve consecutive months after the final menstrual period in the absence of another cause. There is no real-time blood test that can confirm you are menopausal while you are still menstruating. FSH and estradiol levels can support staging, but they are highly variable in perimenopause and should not be used in isolation. If you are on hormonal contraception, have had a hysterectomy with ovarian preservation, or have had endometrial ablation, menstrual cues are unavailable. Clinicians then rely on symptom pattern and selective lab testing (STRAW+10 framework, Harlow et al., 2012).
Can a woman still get pregnant during perimenopause?
Yes. Ovulation becomes irregular during perimenopause but does not stop until the final menstrual period. And that final period is only identifiable in hindsight. ACOG and the Menopause Society advise continuing contraception until twelve consecutive months of amenorrhea if you are over 50, or twenty-four months if you are under 50. Younger perimenopausal women have a higher chance of sporadic ovulation. Pregnancy is not considered a possibility after the 12-month amenorrhea threshold defines menopause.
What is the "timing hypothesis" for hormone therapy?
The timing hypothesis describes the observation that the risk-benefit profile of menopausal hormone therapy depends on your age and years since menopause when you start it. The 18-year follow-up of the Women's Health Initiative (Manson et al., JAMA, 2017) looked at women who started therapy before age 60, or within ten years of the final menstrual period. They had a more favorable mortality profile than those who started later. If you are considering hormone therapy, discuss this evidence with your prescribing physician, who can weigh it against your personal and family risk factors.
How long does perimenopause typically last?
Perimenopause typically lasts four to eight years before the final menstrual period, though the range across populations is wider. The Study of Women's Health Across the Nation (SWAN) longitudinal cohort has documented substantial variability tied to age at onset, ethnicity, smoking status, and parity. Early menopausal transition (Stage −2) can be subtle and lengthy. Late menopausal transition (Stage −1), defined by intervals of ≥60 days of amenorrhea, is usually shorter, often one to three years. Your total transition is best characterized by following your menstrual pattern over time rather than by any single test.
References
- Harlow SD, et al. Menopause. 2012. https://pubmed.ncbi.nlm.nih.gov/22343510/
- American College of Obstetricians and Gynecologists. Obstetrics and Gynecology. 2026. https://www.guidelinecentral.com/guideline/5213608/
- Manson JE, et al. JAMA. 2017. https://pubmed.ncbi.nlm.nih.gov/28898378
- National Heart, Lung, and Blood Institute. National Institutes of Health. 2024. https://www.nhlbi.nih.gov/news/2024/researchers-review-findings-and-clinical-messages-womens-health-initiative-30-years-after
- U.S. Food and Drug Administration. U.S. Food and Drug Administration. 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
- The Menopause Society. The Menopause Society. 2022. https://menopause.org/professional-resources/position-statements
- The Menopause Society. The Menopause Society. 2025. https://menopause.org/press-releases/the-menopause-society-comments-on-the-fda-announcement-on-hormone-therapy
- U.S. Food and Drug Administration. U.S. Food and Drug Administration. 2025. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-lynkuet
- Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. 2024. https://www.cdc.gov/contraception/hcp/usspr/contraception-not-needed.html
- U.S. Preventive Services Task Force. U.S. Preventive Services Task Force. 2025. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
- American Heart Association. American Heart Association. 2026. https://newsroom.heart.org/news/perimenopause-may-offer-a-window-of-opportunity-for-heart-disease-prevention-in-women
About the author
Anna Evans MSN, APRN, FNP-C
Founder, Interlinked Wellness
Anna Evans, MSN, APRN, FNP-C is a board-certified Family Nurse Practitioner licensed in Texas. She founded Interlinked Wellness, a virtual functional medicine practice serving women across Texas from offices in Dallas and Austin. Her clinical focus is perimenopause, hormone imbalance, gut health, thyroid and autoimmune conditions, and chronic fatigue.
More about Anna · Schedule a consultation · LinkedIn · Instagram
For a broader treatment of the transition itself, see the complete guide to perimenopause for women.
Medical disclaimer
The information on this page is provided for general education and is not individualized medical advice. At Interlinked Wellness, Anna Evans, MSN, APRN, FNP-C, provides personalized care based on your health history, symptoms, concerns, and goals. An individual consultation allows Anna to evaluate your specific situation and recommend an appropriate approach to care. Reading this page alone does not establish a patient-provider relationship. If you are experiencing a medical emergency, call 911 or your local emergency services.
Join Anna on a virtual wellness journey and unlock your full potential.
